3 Quantum Computing Stocks with Positive Investor Sentiment – 7/28/2025
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
To find such stocks, take a look at TipRanks' Quantum Computing Stocks page. It allows you to compare stocks based on analyst consensus, price targets, and key technical indicators among others.
When selecting stocks to buy, it can be helpful to consider the sentiments of other individual investors. With that in mind, here are today's top quantum computing stock picks, which have received a bullish investor sentiment signal based on several portfolios analyzed by TipRanks. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.
IonQ (IONQ) – IonQ's advanced trapped-ion technology helps solve complex problems more efficiently than classical computers. It has raised over $1 billion to support its growth and aims to build systems with millions of qubits by 2030. Overall, the analyst consensus on the stock is Strong Buy. Also, the stock has a Positive investor sentiment signal.
D-Wave Quantum (QBTS) – QBTS is known for its Advantage quantum computer, solving problems that classical supercomputers cannot. It is also advancing gate-based tech with fluxonium qubits, aiming for real-world impact and a 100,000-qubit scale. The stock has earned an analyst consensus of Strong Buy. Moreover, QBTS stock has a Positive investor sentiment signal.
Rigetti Computing (RGTI) – RGTI disclosed a 36-qubit multichip system that achieved 99.5% two-qubit gate fidelity, cutting error rates in half compared to previous models. It plans to launch a 100+ qubit system by year-end, using a chiplet design that makes it easier to scale and improve performance. RGTI stock has an analyst consensus of Strong Buy and a Positive investor sentiment signal.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
TransMedics Group Inc (TMDX) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ...
Release Date: July 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points TransMedics Group Inc (NASDAQ:TMDX) reported a 38% year-over-year revenue growth for Q2 2025, reaching $157.4 million. The company achieved a new high water mark for clinical cases and revenue, demonstrating significant operating leverage. TransMedics Group Inc (NASDAQ:TMDX) maintained a steady gross margin of 61.4% in Q2 2025. The company added approximately $90 million to its balance sheet, ending Q2 with over $400 million in cash. TransMedics Group Inc (NASDAQ:TMDX) received FDA conditional approval for the OCS lung IDE and is on track to launch both heart and lung clinical programs before year-end. Negative Points There is market confusion and noise following comments made by a competitor in the organ preservation ecosystem. The company anticipates some minor and transient seasonality in Q3 performance due to summer vacation season. Operating expenses increased by 6% year over year, driven by a 50% increase in R&D expenses. The company faces potential challenges from the US National Transplant modernization initiative, which could impact smaller market players. There is ongoing concern about the impact of oversight on DCD usage, which could affect the company's operations. Q & A Highlights Warning! GuruFocus has detected 4 Warning Sign with TMDX. Q: Can you provide insights on the seasonality impact observed in July and how it compares to last year? A: We are seeing some signs of seasonality, similar to last year, but slightly less pronounced. However, it's still early in the quarter, and we expect some seasonality in Q3 due to various factors. Overall, the impact seems to be slightly less than last year, but it's too early to establish a trend. - Walid Hassanein, President and CEO Q: Are there any concerns about the impact of increased oversight on DCD usage following recent media coverage? A: We believe that some level of oversight could actually benefit the transplant market, especially in DCD. The lack of oversight has led to inefficiencies and lost opportunities for organ preservation. We are confident that our business model can operate effectively in both the current and any future systems. - Walid Hassanein, President and CEO Q: Were there any changes to the lung trial design after discussions with the FDA? A: The clinical trial design remains unchanged. Most of the remaining questions from the FDA are focused on pre-clinical testing. We plan to publish the full design of the clinical program on in late August or early September. - Walid Hassanein, President and CEO Q: What are your thoughts on the US heart market, given the recent flat trend in volumes? A: The heart market has experienced ebbs and flows due to waiting list dynamics. We expect the market to rebound, especially with the introduction of our next-gen heart technology. The growth of DCD and other factors may have temporarily impacted volumes, but we see this as a transient phenomenon. - Walid Hassanein, President and CEO Q: How do you see the NextGen OCS platform impacting lung transplants? A: The NextGen OCS platform is designed to address historical concerns in the US lung perfusion market, such as lung edema and perfusion limitations. We aim to prove the superiority of our platform over cold storage with level one evidence, potentially establishing it as the next standard of care. - Walid Hassanein, President and CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
2 hours ago
- Business Insider
Samsung reports Mobile Experience / Network revenue KRW 3.1T vs. KRW 2.2T y/y
In Q2 Mobile Experience, says: Smartphone shipments decreased compared to Q1 when new models released, Grew both revenue and OP YoY by robust sales of S25 series, A series and Tablets Maintained solid double-digit profitability via efficient resource management. For the second half, Samsung (SSNLF) looks to: Focus on flagship sales of foldables/S25 series and emphasize AI on A series as well as reinforce AI for tablet/wearables and launch new form-factor products such as XR/TriFold to expand ecosystem and pursue solid profitability despite uncertainties and BOM cost burden. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Business Insider
3 hours ago
- Business Insider
Morgan Stanley Keeps Their Buy Rating on Tuas Ltd. (TUA)
In a report released today, James Bales from Morgan Stanley maintained a Buy rating on Tuas Ltd., with a price target of A$7.00. The company's shares opened today at A$5.13. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Bales is a 2-star analyst with an average return of 0.4% and a 40.96% success rate. Bales covers the Consumer Cyclical sector, focusing on stocks such as Collins Foods , Corporate Travel Management Limited, and Temple & Webster Group Ltd. In addition to Morgan Stanley, Tuas Ltd. also received a Buy from Citi's William Park CPA in a report issued on July 29. However, on July 28, TR | OpenAI – 4o initiated coverage with a Hold rating on Tuas Ltd. (ASX: TUA).
